




The **right** course of action.
For the **right** patient.
At the **right** time.
All with the **right** tests.




Feel more secure when managing COVID-19 patient risk


CD4⁺ and CD8⁺ T-cells are important in viral killing and antibody response and are often decreased in severe COVID-19¹. T-cell lymphocytes (CD4⁺ and/or CD8⁺) counts at hospitalization can aid in determining the relative risks of Intubation with Mechanical Ventilation (IMV) and of mortality, in conjunction with clinical findings and the results of other laboratory procedures. **These relative risks are ~5–6x higher for IMV and 4.5x higher for mortality for patients with T-cell subset counts below cut-off levels (CD4⁺<250 cells/μl and/or CD8⁺<100 cells/μl).***



T-cell counts aid in determining risk of Intubation with Mechanical Ventilation (IMV)



IMV-free probability for patients above and below CD4⁺ and CD8⁺ T-cell cut-offs*




CD4 ⁺ and CD8 ⁺ T-cell absolute counts (cells/μl)		Number of Patients				
CD4 ⁺ ≥250 and CD8 ⁺ ≥100	112	34	13	3	1	
CD4 ⁺ <250 and CD8 ⁺ ≥100	11	4	0	0	0	
CD4 ⁺ ≥250 and CD8 ⁺ <100	8	5	1	0	0	
CD4 ⁺ <250 and CD8 ⁺ <100	10	3	0	0	0	

Use the **BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes** to augment COVID-19 patient workup. This test generates the percentages and absolute counts of T, B and natural killer (NK) cells as well as the CD4⁺ and CD8⁺ subpopulations of T-cells in peripheral blood. This is a trusted test now with clinically validated and actionable cut-off values for specific lymphocyte T-cells subsets (CD4⁺ and/or CD8⁺) to identify COVID-19 patients at increased risk for IMV, and increased risk of mortality at hospital admission, in conjunction with clinical findings and the results of other laboratory testing.

1. Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: A meta-analysis. *Cytometry A*. 2020;97(8):772-776. doi: 10.1002/cyto.a.24172
*bdbiosciences.com/Covid-19-TBNK-IFU For additional information: bdbiosciences.com/en-eu/applications/clinical-applications/covid-19-tcell

BD, the BD Logo, Multitest and Trucount are trademarks of Becton, Dickinson and Company or its affiliates. © 2021 BD. All rights reserved. BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes is CE marked in compliance with the European In Vitro Diagnostic Medical Device Directive 98/79/EC. BD-25620 (v1.0) 0121



Reference

1. Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: A meta-analysis. *Cytometry A*. 2020;97(8):772-776. doi: 10.1002/cyto.a.24172

bdbiosciences.com/Covid-19-TBNK-IFU

For additional information:

bdbiosciences.com/en-eu/applications/clinical-applications/covid-19-tcell

BD Life Sciences, San Jose, CA, 95131, USA

bdbiosciences.com

BD, the BD Logo, Multitest and Trucount are trademarks of Becton, Dickinson and Company or its affiliates. © 2021 BD.

All rights reserved. BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes is CE marked in compliance with the European In Vitro Diagnostic Medical Device Directive 98/79/EC. BD-25632 (v1.0) 0121

